Rapport Therapeutics (RAPP) Assets Average (2024 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Assets Average of $505.0 million for Q1 2026, up 63.7% year-over-year from $308.5 million in Q1 2025, and down 3.6% quarter-over-quarter from $523.9 million in Q4 2025.
Rapport Therapeutics (RAPP) Assets Average (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Assets Average for 3 consecutive years, with $505.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 63.7% year-over-year to $505.0 million; the TTM figure through Mar 2026 stood at $505.0 million (up 63.7% YoY), while the FY2025 annual figure was $413.7 million, up 75.9% from the prior year.
- Assets Average declined to $505.0 million in Q1 2026 per RAPP's latest filing, from $523.9 million in the prior quarter.
- Across five years, Assets Average topped out at $523.9 million in Q4 2025 and bottomed at $293.8 million in Q2 2025.
- Historically, Assets Average has averaged $386.2 million across 3 years, with a median of $338.6 million in 2024.
- Annual changes were most pronounced in 2025 — Assets Average advanced 21.2% — and 2026, when it surged 63.7%.
- Rapport Therapeutics' Assets Average stood at $323.0 million in 2024, then jumped by 62.17% to $523.9 million in 2025, then fell by 3.6% to $505.0 million in 2026.
- Business Quant data shows RAPP's Assets Average at $505.0 million in Q1 2026, $523.9 million in Q4 2025, and $410.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 478.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 478.29 Mn |
| Mar 31, 2026 | 505.01 Mn |
| Dec 31, 2025 | 523.88 Mn |
| Sep 30, 2025 | 410.41 Mn |
| Jun 30, 2025 | 293.77 Mn |
| Mar 31, 2025 | 308.49 Mn |
| Dec 31, 2024 | 323.04 Mn |
| Sep 30, 2024 | 338.62 Mn |